Volrustomig
Based on 1 Customer Validation
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1+ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1+ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer.
For research use only. We do not sell to patients.
- Purity : ≥99.0%
- CAS No.: 2407760-40-9
- Molecular Weight:146.51 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CTLA4 & PDCD1
In Vitro
Volrustomig potently inhibits CTLA-4 binding on PD-1-positive activated T cells (IC50 0.01 nmol/L) and is significantly less potent against PD-1-negative T cells (IC50 4.6 nmol/L)[4].
Volrustomig provides comparable sustained PD-1 binding and significantly more potent CTLA-4 binding on activated T cells compared to coadministered conventional bivalent anti-PD-1 and anti-CTLA-4 monoclonal antibodies[4].
Volrustomig (6 hours) induces >90% downregulation of cell surface PD-1 on activated T cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa_VK-CL_3bridges
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Volrustomig (anti-CTLA4) (HY-P990690). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Flow Cytometry analysis of THP-1 cells labelling PDCD1 (red) with Volrustomig (anti-PDCD1) (HY-P990690). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2407760-40-9
-
Appearance Liquid
-
Molecular Weight 146.51 kDa
-
Color Colorless to light yellow
-
Synonyms
MEDI-5752
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[3]. Bose CK, et al. Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer. J Gynecol Oncol. 2024;35(4):e82. [Content Brief]
[4]. Tran B, et al. Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody. Clin Cancer Res. Published online February 17, 2026. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)